Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Trifarma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Expert Take on CEP 2.0: A New Era of Transparency in Pharmaceutical Regulation

    micExpert Take on CEP 2.0: A New Era of Transparency in Pharmaceutical Regulation

    At the recent EDQM conference “Certified for Success: Using the CEP Procedure to Elevate Quality and Drive Trust,” regulatory leaders gathered to discuss one of the most significant shifts in European pharmaceutical oversight recently– the transition to CEP 2.0. In the following article, Karina Boszko, Head of Global Regulatory Affairs and Customer Technical Service at Polpharma API, shares her perspective on the new framework and its impact on transforming regulatory strategies for manufacturers worldwide. A strategic shift beyond just compliance. CEP 2.0 is more than a routine update. It represents a fundamental change in how pharmaceutical companies approach transparency, lifecycle management, and international expansion. Rather than focusing solely on documentation, the framework encourages organizations to treat regulatory excellence as a strategic differentiator, shifting the mindset from static compliance to continuous lifecycle oversight. Regulatory alignment thus becomes a living process that evolves with the product, data, and technology. Embedding this approach across teams will foster a culture of iterative improvement, innovation, and stronger organizational resilience. For many manufacturers, however, this will require introducing significant internal changes, from documentation practices to cross-functional collaboration. CEP 2.0 means faster timelines and higher predictability. But only if your team is ready. One of the most anticipated benefits of CEP 2.0 is more predictable review timelines and consistent submissions. However, leveraging these advantages depends heavily on industry readiness. Regulatory teams must adapt to more streamlined, data-driven processes and ensure that digital tools, training, and workflows support accelerated operations. Organizations that modernize will see multiple operational benefits early, including faster project completion, reduced rework, and quicker access to key markets as standardized documentation and cohesive global expectations will make previously complex or "slow” markets more accessible. For companies pursuing international expansion, CEP 2.0 provides a clearer path to global approvals, cross-market consistency, and enhanced competitiveness. Balancing challenges with opportunity. Despite its promise, the transition to CEP 2.0 is not without challenges. Data privacy, operational costs, supply chain complexity, and pressure on low-margin APIs remain key industry concerns that require striking a balance between stringent compliance and long-term sustainability. Still, companies that efficiently integrate regulatory requirements into scalable operations will not only demonstrate the maturity of their quality systems but also build trust externally, strengthening their reputation and differentiating their business in an increasingly competitive market. Looking ahead to a more collaborative future. CEP 2.0 positions the pharmaceutical sector for a future where regulatory excellence drives global competitiveness. Transparency, harmonization, and a lifecycle approach will increasingly define market leaders. The framework’s success, however, requires ongoing dialogue with regulators. Clear, practical guidance from the EDQM, combined with active feedback from manufacturers, is essential. The more open the collaboration, the more effectively CEP 2.0 will support innovation, quality, and patient safety. The question for every organization is how to approach this moment: as a compliance burden, or as a strategic opportunity to elevate quality, accelerate growth, and build long-term trust. Connect with Polpharma API: Your Partner in Pharma AdvancementFor more information on how Polpharma API can be your strategic ally in drug substance development and manufacturing, contact us at api@polpharma.comLet's embark on a journey of innovation and excellence together.

    Impressions: 134

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/expert-take-on-cep-2-0-a-new-era-of-transparency-in-pharmaceutical-regulation

    PharmaCompass
    13 Feb 2026
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaSmart & Innovative Custom ManufacturingSmart & Innovative Custom Manufacturing

    Smart & Innovative Custom Manufacturing
    Smart & Innovative Custom Manufacturing

    reelSmart & Innovative Custom Manufacturing

    This PharmaReel highlights PMC Isochem, a smart custom manufacturing partner that offers Generic APIs, cGMP Intermediates, Vitamin E TPGS, and cutting-edge drug delivery materials, supported by trusted CDMO & CRO services and certified by the USFDA and EDQM.

    Impressions: 77

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    This week, PharmaCompass brings you key highlights of the US Food and Drug Administration’s December 2025 list of Off-Patent, Off-Exclusivity Drugs (OPOE) without an approved generic. The OPOE list gets updated every six months.This list highlights drug products that have lost patent protection and regulatory exclusivity, but remain without approved generic competition in the US market. With this list, the FDA hopes to bolster competitiveness in the generics market, improve transparency and encourage the development and submission of abbreviated new drug applications (ANDAs) in markets with little competition.Since December 2021, FDA has been publishing two versions of the OPOE list — one for prescription (Rx) drug products and the other for over-the-counter (OTC) drug products that are approved and marketed under a new drug approval (NDA).  Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel)Injectables continue to dominate FDA’s OPOE Rx list; 73 OTC drugs figure in Dec listFDA’s December 2025 OPOE Rx list includes 784 drug products that currently have no approved generics. Out of these, 296 are injectables and 126 are oral solid dosage forms (such as tablets, capsules and modified release forms). In June 2025, the OPOE Rx list had 765 drug products without an approved generic, out of which 304 were injectables, while 109 were oral solid drug forms. The increase in drug products from 765 to 784 from June 2025 to December 2025 was due to the inclusion of additional dosage strengths in the OPOE Rx list. Otherwise, no new drugs were added to the December 2025 OPOE Rx list.The December 2025 OPOE list has 73 OTC drugs, slightly higher than the 69 drugs in the June 2025 list. Among the 73, 21 are oral solid dosage forms.Among the OTC drugs on the December 2025 OPOE list are ibuprofen and ibuprofen sodium (for pain and inflammation), pseudoephedrine hydrochloride and phenylephrine hydrochloride (nasal decongestants), nizatidine and famotidine (for gastroesophageal reflux disease), loratadine, cetirizine hydrochloride and chlorpheniramine maleate (for allergy relief), loperamide hydrochloride (anti-diarrheal), and orlistat (for weight management). Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel)FDA fast-tracks initiatives to accelerate market entry of generics, biosimilarsFDA has launched several regulatory initiatives designed to accelerate the market entry of generics and biosimilars. In October 2025, the agency announced a new pilot prioritization program for the review of ANDAs that aims to encourage and reward investment in drug manufacturing, research and development and strengthen the pharmaceutical supply chain in the United States.Separately, FDA has also come out with a new draft guidance that seeks to simplify biosimilarity studies and reduce unnecessary clinical testing. Through a separate initiative, the agency also plans to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, thereby helping patients and pharmacists choose lower-cost options. Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel) Our viewThe global generic drugs market was valued at US$ 445.62 billion in 2024 and is projected to reach US$ 728.64 billion by 2034, growing at a compound annual growth rate of 5.04 percent from 2025 to 2034. With several diabetes, immunology, oncology and cardiology drugs slated to face patent expirations this year, and continued pressure on drugmakers to improve affordability, we believe the generic market could grow at an even faster rate in the near term.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1598

    https://www.pharmacompass.com/radio-compass-blog/fda-opoe

    #PharmaFlow by PHARMACOMPASS
    22 Jan 2026
    Share Share

    NEWS #PharmaBuzz

    [Sponsored by another company]read-more
    read-more
    Trifarma S.P.A on Health Canada Inspection List
    Trifarma S.P.A on Health Canada Inspection List

    07 Dec 2022

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/trifarma-spa-on-health-canada-inspection-list-71711.pdf

    HEALTH CANADA
    07 Dec 2022
    Share Share
    Trifarma S.p.A. Fails EDQM Inspection
    Trifarma S.p.A. Fails EDQM Inspection

    26 Oct 2022

    // EDQM

    https://www.pharmacompass.com/pdf/news/trifarma-spa-fails-edqm-inspection-92992.pdf

    EDQM
    26 Oct 2022
    Share Share
    Alchymars ICM SM Private Limited Placed on FDA Import Alert List
    Alchymars ICM SM Private Limited Placed on FDA Import Alert List

    15 Feb 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/alchymars-icm-sm-private-limited-placed-on-fda-import-alert-list-1550215883.pdf

    FDA
    15 Feb 2019
    Share Share
    FDA slams Indian drugmaker for filthy plant, data falsification
    FDA slams Indian drugmaker for filthy plant, data falsification

    28 Feb 2018

    // Eric Palmer FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/fda-warning-savages-indian-drugmaker-for-filthy-plant-data-falsification

    Eric Palmer FIERCE PHARMA
    28 Feb 2018
    Share Share
    Alchymars ICM SM Private Limited Receives FDA Warning Letter
    Alchymars ICM SM Private Limited Receives FDA Warning Letter

    27 Feb 2018

    // FDA

    https://www.pharmacompass.com/pdf/news/alchymars-icm-sm-private-limited-receives-fda-warning-letter-1519753913.pdf

    FDA
    27 Feb 2018
    Share Share
    India woos Italian bulk drug makers to cut dependency on Chinese APIs
    India woos Italian bulk drug makers to cut dependency on Chinese APIs

    13 Aug 2015

    // Raji Reddy Kesireddy THE ECONOMIC TIMES

    http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-woos-italian-bulk-drug-makers-to-cut-dependency-on-chinese-apis/articleshow/48446172.cms

    Raji Reddy Kesireddy THE ECONOMIC TIMES
    13 Aug 2015
    Share Share
    Contact Trifarma and get a quotation

    Trifarma is a supplier offers 52 products (APIs, Excipients or Intermediates).

    Find a price of Clindamycin Phosphate bulk with DMF, JDMF offered by Trifarma

    Find a price of Minoxidil bulk with DMF, CEP offered by Trifarma

    Find a price of Clocortolone Pivalate bulk with DMF offered by Trifarma

    Find a price of Epinastine Hydrochloride bulk with DMF offered by Trifarma

    Find a price of Fluphenazine bulk with DMF offered by Trifarma

    Find a price of Fluphenazine Decanoate bulk with DMF offered by Trifarma

    Find a price of Foscarnet Sodium bulk with DMF offered by Trifarma

    Find a price of Ganciclovir bulk with DMF offered by Trifarma

    Find a price of Halobetasol bulk with DMF offered by Trifarma

    Find a price of Hydrocortisone Valerate bulk with DMF offered by Trifarma

    Find a price of Oxandrolone bulk with DMF offered by Trifarma

    Find a price of Perphenazine bulk with DMF offered by Trifarma

    Find a price of Prochlorperazine bulk with DMF offered by Trifarma

    Find a price of Prochlorperazine Edisylate bulk with DMF offered by Trifarma

    Find a price of Prochlorperazine Maleate bulk with DMF offered by Trifarma

    Find a price of Testosterone Cypionate bulk with DMF offered by Trifarma

    Find a price of Thioridazine Hydrochloride bulk with DMF offered by Trifarma

    Find a price of Tranylcypromine Sulfate bulk with DMF offered by Trifarma

    Find a price of Trifluoperazine Hydrochloride bulk with DMF offered by Trifarma

    Find a price of Zoledronic Acid bulk with DMF offered by Trifarma

    Find a price of Alendronate Sodium bulk offered by Trifarma

    Find a price of Alendronic Acid Monohydrate bulk offered by Trifarma

    Find a price of Benzhexol hydrochloride bulk offered by Trifarma

    Find a price of Chlorpromazine Hydrochloride bulk offered by Trifarma

    Find a price of Clocortolone Pivalate bulk offered by Trifarma

    Find a price of Exemestane bulk offered by Trifarma

    Find a price of Fosphenytoin Sodium bulk offered by Trifarma

    Find a price of Furosemide bulk offered by Trifarma

    Find a price of Glibenclamide bulk offered by Trifarma

    Find a price of Oxcarbazepine bulk offered by Trifarma

    Find a price of Procyclidine bulk offered by Trifarma

    Find a price of Selegiline Hydrochloride bulk offered by Trifarma

    Find a price of Tranylcypromine Sulfate bulk offered by Trifarma

    Find a price of Adenosine bulk offered by Trifarma

    Find a price of Ambroxol Hydrochloride bulk offered by Trifarma

    Find a price of Bromfenac Sodium bulk offered by Trifarma

    Find a price of Clindamycin Hydrochloride bulk offered by Trifarma

    Find a price of Clomipramine Hydrochloride bulk offered by Trifarma

    Find a price of Disodium Pamidronate Pentahydrate bulk offered by Trifarma

    Find a price of Hydralazine Hydrochloride bulk offered by Trifarma

    Find a price of Ibandronate Sodium bulk offered by Trifarma

    Find a price of Loteprednol Etabonate bulk offered by Trifarma

    Find a price of Methadone Hydrochloride bulk offered by Trifarma

    Find a price of Milrinone bulk offered by Trifarma

    Find a price of Minoxidil bulk offered by Trifarma

    Find a price of Nicorandil bulk offered by Trifarma

    Find a price of Perazine Dimalonate bulk offered by Trifarma

    Find a price of Risedronate Sodium bulk offered by Trifarma

    Find a price of Sodium Nitroprusside bulk offered by Trifarma

    Find a price of Tetracycline bulk offered by Trifarma

    Find a price of Triclofos Sodium bulk offered by Trifarma

    Find a price of Warfarin Sodium bulk offered by Trifarma

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.